crozbaciclib

Crozbaciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of malignant gliomas, including glioblastoma multiforme.[1][5][9][15][18] As a selective CDK4/6 blocker with low-nanomolar potency, it is designed to inhibit phosphorylation of the retinoblastoma (Rb) protein, thereby enforcing G1 cell-cycle arrest and suppressing proliferation in tumors driven by dysregulated CDK4/6–cyclin D–Rb signaling.[5][7][17] Preclinical orthotopic xenograft models of glioblastoma have shown robust tumor growth inhibition with crozbaciclib, and the fumarate salt form has received US FDA orphan drug designation for the treatment of malignant glioma.[1][5][18]

Other names

crozbaciclib fumarate